In Alzheimer's disease (AD), impaired glymphatic function is tightly linked to the accumulation of amyloid-β (Aβ) plaques and hyperphosphorylated tau (p-tau) proteins,9–11 both of which are the pathological hallmarks of AD.12–14. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.